Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,374 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo, Cohort 2 Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

NCT04270682
View directory record Official record
Conditions
CTX
Interventions
Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Month and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Aurora, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 21, 2026, 5:31 AM EDT
Not yet recruiting Phase 2 Interventional

Role of Omega-DEK in Childhood Apraxia of Speech

NCT07216001
View directory record Official record
Conditions
Childhood Apraxia of Speech, Verbal Apraxia, Autism
Interventions
Omega-DEK, L-carnitine, Placebo
Drug
Lead sponsor
Claudia R. Morris
Other
Eligibility
36 Months to 6 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 21, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional Results available

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 5 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
41
States / cities
Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral capsule, Placebo oral capsule
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 21, 2026, 5:31 AM EDT
Active, not recruiting No phase listed Observational

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

NCT01517945
View directory record Official record
Conditions
Breast Cancer, Rare Cancer
Interventions
AIM materials and assessments
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Results available

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

NCT02542605
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, PACAP-38 Challenge Agent
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

NCT01343966
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 21, 2026, 5:31 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 21, 2026, 5:31 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 21, 2026, 5:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

NCT04520139
View directory record Official record
Conditions
Ovarian Cancer, Cognitive Impairment
Interventions
N-Acetyl-Cysteine, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 21, 2026, 5:31 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

NCT02228395
View directory record Official record
Conditions
Healthy
Interventions
PF-04958242, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

NCT02153099
View directory record Official record
Conditions
Dose Finding Study
Interventions
TAK-058 (ENV8058), Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Results available

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

NCT05696847
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

NCT01749878
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
REGN1500, placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men

NCT01674036
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Genz-682452, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

NCT03545438
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LIB003
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03524092
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab SC, Mirikizumab IV, Placebo SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
57
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

NCT00135707
View directory record Official record
Conditions
Preeclampsia
Interventions
Dietary Supplement/Vitamins, Placebo for Vitamin C and Vitamin E
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
10,154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
16
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 21, 2026, 5:31 AM EDT
Recruiting Phase 2 Interventional

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

NCT07220811
View directory record Official record
Conditions
Ig-E Mediated Food Allergy
Interventions
RPT904, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc.
Industry
Eligibility
12 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

NCT02512588
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
BTD-001, Placebo
Drug
Lead sponsor
Balance Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 21, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

NCT01203943
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, Interstitial Lung Disease, Lung Diseases, Interstitial
Interventions
CC-930, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
50 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Sacramento, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 21, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

NCT06178991
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
8,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
106
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 21, 2026, 5:31 AM EDT